Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study

Detalhes bibliográficos
Autor(a) principal: Drummond, Paula Lana de Miranda
Data de Publicação: 2022
Outros Autores: Santos, Roberta Márcia Marques dos, Reis, Adriano Max Moreira, Malta, Jéssica Soares, Silveira, Lívia Pena, Costa, Iwyson Henrique Fernandes da, Marques, Bárbara Soares Diniz, Silva, Roberta Oliveira de Paula e, Fagundes, Evandro Maranhão, Colosimo, Enrico Antônio, Pádua, Cristiane Aparecida Menezes de
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/34709
Resumo: Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment.
id UNIFEI_e1da9985127d1b78cb714714bba95400
oai_identifier_str oai:ojs.pkp.sfu.ca:article/34709
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study Calidad de vida relacionada con la salud de pacientes con mieloma múltiple después del tratamiento de primera línea: resultados de un estudio de cohorte prospectivoQualidade de vida relacionada à saúde de pacientes com mieloma múltiplo após o tratamento de primeira linha: resultados de um estudo de coorte prospectiva Mieloma MúltipleCalidad de VidaTalidomidaBortezomibEnfermedades del Sistema Nervioso Periférico.Mieloma múltiploQualidade de vidaTalidomidaBortezomibeNeuropatias periféricas.Multiple MyelomaQuality of lifeThalidomideBortezomibPeripheral neuropathy.Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment.Objetivo: El objetivo fue evaluar si hubo una mejora o empeoramiento en la calidad de vida relacionada con la salud (CVRS) de pacientes con mieloma múltiple (MM) y factores asociados a la CVRS después de 12 meses de tratamiento. Métodos: Se realizó un estudio de cohorte prospectivo con pacientes con MM en tratamiento de primera línea en servicios oncohematológicos de Brasil. Se obtuvieron variables clínicas, sociodemográficas y CVRS a través de entrevistas y revisión de historias médicas. La CVRS y la neuropatía periférica (NP) se recogieron mediante instrumentos validados. Se compararon las puntuaciones medianas de la CVRS obtenidas de las entrevistas iniciales y de seguimiento. Se midió la mejora o empeoramiento de la CVRS y la asociación con variables. Resultados: Treinta y tres pacientes completaron el seguimiento, con ISS III (25,0%), polifarmacia (72,2%), usando talidomida+bortezomib como primera línea (19,4%), y una mediana de edad de 66,5 años. La puntuación resumida, las escalas funcionales y de síntomas y la perspectiva futura mejoraron entre períodos (p<0,05). Los pacientes en polifarmacia, con NP grave e ISS III presentaron empeoramiento de la CVRS; los pacientes más jóvenes mejoraron y los pacientes mayores empeoraron en CVRS (p<0,05). Conclusiones: El tratamiento de primera línea mejoró la CVRS de los pacientes en las siguientes escalas QLQ-C30: puntuación resumida, escala funcional y emocional, fatiga, dolor y estreñimiento; y en QLQ-MY20, la perspectiva de futuro ha mejorado. Nuestro estudio muestra la importancia de utilizar los resultados informados por los pacientes durante el tratamiento del MM.Objetivo: O objetivo foi avaliar se houve melhora ou piora da qualidade de vida relacionada à saúde (QVRS) de pacientes com mieloma múltiplo (MM) e fatores associados à QVRS após 12 meses de tratamento. Métodos: Realizou-se estudo de coorte prospectiva com pacientes com MM em tratamento de primeira linha em serviços de saúde de onco-hematologia públicos e privado no Brasil. QVRS, variáveis sociodemográficas e clínicas foram obtidas por meio de entrevistas e revisão de prontuários. QVRS e neuropatia periférica (NP) foram coletadas por meio de instrumentos validados (QLQ-C30, QLQ-MY20, CINQ). As medianas dos escores de QVRS, obtidos nas entrevistas basais e de seguimento, foram comparadas. Os escores medianos de QVRS no seguimento foram comparados por variáveis. A melhora ou piora da QVRS e a associação com variáveis foram mensuradas. Resultados: Trinta e três pacientes completaram o seguimento, com ISS III (25,0 %), polifarmácia (72,2 %), em uso de talidomida+bortezomibe como primeira linha (19,4 %), e idade mediana de 66,5 anos. O Escore sumarizado, escalas Funcionais e de Sintomas e Perspectiva Futura melhoraram entre os períodos (p<0,05). Pacientes em polifarmácia, com NP grave e ISS III apresentaram piora da QVRS; pacientes mais jovens tiveram melhora e pacientes mais velhos pioraram na QVRS (p<0,05). Conclusões: O tratamento de primeira linha melhorou a QVRS dos pacientes nas seguintes escalas QLQ-C30: escore sumarizado, escala funcional, escala emocional, fadiga, dor e constipação; e no QLQ-MY20, a perspectiva futura melhorou. Nosso estudo mostra a importância de usar resultados relatados pelo paciente durante o tratamento do MM.Research, Society and Development2022-09-17info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3470910.33448/rsd-v11i12.34709Research, Society and Development; Vol. 11 No. 12; e351111234709Research, Society and Development; Vol. 11 Núm. 12; e351111234709Research, Society and Development; v. 11 n. 12; e3511112347092525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/34709/29162Copyright (c) 2022 Paula Lana de Miranda Drummond; Roberta Márcia Marques dos Santos; Adriano Max Moreira Reis; Jéssica Soares Malta; Lívia Pena Silveira; Iwyson Henrique Fernandes da Costa; Bárbara Soares Diniz Marques; Roberta Oliveira de Paula e Silva; Evandro Maranhão Fagundes; Enrico Antônio Colosimo; Cristiane Aparecida Menezes de Páduahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessDrummond, Paula Lana de Miranda Santos, Roberta Márcia Marques dos Reis, Adriano Max MoreiraMalta, Jéssica Soares Silveira, Lívia Pena Costa, Iwyson Henrique Fernandes da Marques, Bárbara Soares Diniz Silva, Roberta Oliveira de Paula e Fagundes, Evandro Maranhão Colosimo, Enrico AntônioPádua, Cristiane Aparecida Menezes de 2022-09-26T11:56:08Zoai:ojs.pkp.sfu.ca:article/34709Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:49:54.096327Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
Calidad de vida relacionada con la salud de pacientes con mieloma múltiple después del tratamiento de primera línea: resultados de un estudio de cohorte prospectivo
Qualidade de vida relacionada à saúde de pacientes com mieloma múltiplo após o tratamento de primeira linha: resultados de um estudo de coorte prospectiva
title Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
spellingShingle Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
Drummond, Paula Lana de Miranda
Mieloma Múltiple
Calidad de Vida
Talidomida
Bortezomib
Enfermedades del Sistema Nervioso Periférico.
Mieloma múltiplo
Qualidade de vida
Talidomida
Bortezomibe
Neuropatias periféricas.
Multiple Myeloma
Quality of life
Thalidomide
Bortezomib
Peripheral neuropathy.
title_short Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
title_full Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
title_fullStr Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
title_full_unstemmed Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
title_sort Health-related quality of life of multiple myeloma patients after the first-line treatment: results of a prospective cohort study
author Drummond, Paula Lana de Miranda
author_facet Drummond, Paula Lana de Miranda
Santos, Roberta Márcia Marques dos
Reis, Adriano Max Moreira
Malta, Jéssica Soares
Silveira, Lívia Pena
Costa, Iwyson Henrique Fernandes da
Marques, Bárbara Soares Diniz
Silva, Roberta Oliveira de Paula e
Fagundes, Evandro Maranhão
Colosimo, Enrico Antônio
Pádua, Cristiane Aparecida Menezes de
author_role author
author2 Santos, Roberta Márcia Marques dos
Reis, Adriano Max Moreira
Malta, Jéssica Soares
Silveira, Lívia Pena
Costa, Iwyson Henrique Fernandes da
Marques, Bárbara Soares Diniz
Silva, Roberta Oliveira de Paula e
Fagundes, Evandro Maranhão
Colosimo, Enrico Antônio
Pádua, Cristiane Aparecida Menezes de
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Drummond, Paula Lana de Miranda
Santos, Roberta Márcia Marques dos
Reis, Adriano Max Moreira
Malta, Jéssica Soares
Silveira, Lívia Pena
Costa, Iwyson Henrique Fernandes da
Marques, Bárbara Soares Diniz
Silva, Roberta Oliveira de Paula e
Fagundes, Evandro Maranhão
Colosimo, Enrico Antônio
Pádua, Cristiane Aparecida Menezes de
dc.subject.por.fl_str_mv Mieloma Múltiple
Calidad de Vida
Talidomida
Bortezomib
Enfermedades del Sistema Nervioso Periférico.
Mieloma múltiplo
Qualidade de vida
Talidomida
Bortezomibe
Neuropatias periféricas.
Multiple Myeloma
Quality of life
Thalidomide
Bortezomib
Peripheral neuropathy.
topic Mieloma Múltiple
Calidad de Vida
Talidomida
Bortezomib
Enfermedades del Sistema Nervioso Periférico.
Mieloma múltiplo
Qualidade de vida
Talidomida
Bortezomibe
Neuropatias periféricas.
Multiple Myeloma
Quality of life
Thalidomide
Bortezomib
Peripheral neuropathy.
description Objective: The aim of this study was to evaluate whether there was an improvement or a deterioration of health-related quality of life (HRQoL) of multiple myeloma patients (MM), and to assess the associated factors with HRQoL after 12 months of treatment. Methods: We performed a prospective cohort study with MM patients in first-line treatment from public and private onco-hematology health services in a Brazilian metropolis. HRQoL, socio-demographic and clinical variables were obtained by interviews and review of medical charts. HRQoL and peripheral neuropathy (PN) were collected through validated instruments (QLQ-C30, QLQ-MY20, CINQ). Medians of the HRQoL scores, obtained at baseline and follow-up interviews, were compared. Median HRQOL scores at follow-up were compared by variables. The improvement or deterioration in HRQoL and the association with variables were measured. Results: Thirty-three patients completed the follow-up, with ISS III (25.0 %), on polypharmacy (72.2 %), using a thalidomide+bortezomib-based regimen as first-line (19.4 %), and median age of 66.5 years. HRQoL Summary score, Functioning, Symptom scales, and Future Perspective scores were improved between periods (p<0.05). Patients who were on polypharmacy, with severe PN, and with ISS III had deterioration in HRQoL; younger patients had improvement and older patients had deterioration in HRQoL (p<0.05). Conclusions: Our study showed that first-line treatment improved HRQoL of patients in the following QLQ-C30 scales: Summary score, Role functioning, Emotional functioning, Fatigue, Pain, and Constipation; and in QLQ-MY20, Future perspective was improved. Our study shows the importance of using patient-reported outcomes during MM treatment.
publishDate 2022
dc.date.none.fl_str_mv 2022-09-17
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/34709
10.33448/rsd-v11i12.34709
url https://rsdjournal.org/index.php/rsd/article/view/34709
identifier_str_mv 10.33448/rsd-v11i12.34709
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/34709/29162
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 12; e351111234709
Research, Society and Development; Vol. 11 Núm. 12; e351111234709
Research, Society and Development; v. 11 n. 12; e351111234709
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052723582992384